tetano
Editor, Senior Moderator
Isr Med Assoc J
. 2024 Jan;26(1):12-17.
Obstetric and Early Neonatal Outcomes Following Second and Third COVID-19 Vaccination in Pregnancy
Ravit Peretz-Machluf[SUP] 1 [/SUP], Mayan Gilboa[SUP] 2 [/SUP], Shiran Bookstein-Peretz[SUP] 1 [/SUP], Omri Segal[SUP] 1 [/SUP], Noam Regev[SUP] 1 [/SUP], Raanan Meyer[SUP] 1 [/SUP], Gili Regev-Yochay[SUP] 2 [/SUP], Yoav Yinon[SUP] 1 [/SUP], Shlomi Toussia-Cohen[SUP] 1 [/SUP]
Affiliations
Background: Pregnant women are at higher risk for severe coronavirus disease 2019 (COVID-19). Since the release of the BNT162b2 messenger RNA vaccine (Pfizer/BioNTech), there has been accumulated data about the three vaccine doses. However, information regarding obstetric and neonatal outcomes of pregnant women vaccinated with the third (booster) vaccine is limited and primarily retrospective.
Objectives: To evaluate the obstetric and early neonatal outcomes of pregnant women vaccinated during pregnancy with the COVID-19 booster vaccine compared to pregnant women vaccinated only by the first two doses.
Methods: We conducted a cross-sectional study of pregnant women who received the BNT162b2 vaccine during pregnancy. Obstetric and neonatal outcomes were compared between pregnant women who received only the first two doses of the vaccine to those who also received the booster dose.
Results: Overall, 139 pregnant women were vaccinated during pregnancy with the first two doses of the vaccine and 84 with the third dose. The third dose group received the vaccine earlier during their pregnancy compared to the two doses group (212 vs. 315 weeks, respectively, P < 0.001). No differences in obstetric and early neonatal outcomes between the groups were found except for lower rates of urgent cesarean delivery in the third dose group (adjusted odds ratio 0.21; 95% confidence interval 0.048-0.926, P = 0.039).
Conclusions: Compared to the first two doses of the BNT162b2 vaccine given in pregnancy, the booster vaccination is safe and not associated with an increased rate of adverse obstetric and early neonatal outcomes.
. 2024 Jan;26(1):12-17.
Obstetric and Early Neonatal Outcomes Following Second and Third COVID-19 Vaccination in Pregnancy
Ravit Peretz-Machluf[SUP] 1 [/SUP], Mayan Gilboa[SUP] 2 [/SUP], Shiran Bookstein-Peretz[SUP] 1 [/SUP], Omri Segal[SUP] 1 [/SUP], Noam Regev[SUP] 1 [/SUP], Raanan Meyer[SUP] 1 [/SUP], Gili Regev-Yochay[SUP] 2 [/SUP], Yoav Yinon[SUP] 1 [/SUP], Shlomi Toussia-Cohen[SUP] 1 [/SUP]
Affiliations
- PMID: 38420636
Background: Pregnant women are at higher risk for severe coronavirus disease 2019 (COVID-19). Since the release of the BNT162b2 messenger RNA vaccine (Pfizer/BioNTech), there has been accumulated data about the three vaccine doses. However, information regarding obstetric and neonatal outcomes of pregnant women vaccinated with the third (booster) vaccine is limited and primarily retrospective.
Objectives: To evaluate the obstetric and early neonatal outcomes of pregnant women vaccinated during pregnancy with the COVID-19 booster vaccine compared to pregnant women vaccinated only by the first two doses.
Methods: We conducted a cross-sectional study of pregnant women who received the BNT162b2 vaccine during pregnancy. Obstetric and neonatal outcomes were compared between pregnant women who received only the first two doses of the vaccine to those who also received the booster dose.
Results: Overall, 139 pregnant women were vaccinated during pregnancy with the first two doses of the vaccine and 84 with the third dose. The third dose group received the vaccine earlier during their pregnancy compared to the two doses group (212 vs. 315 weeks, respectively, P < 0.001). No differences in obstetric and early neonatal outcomes between the groups were found except for lower rates of urgent cesarean delivery in the third dose group (adjusted odds ratio 0.21; 95% confidence interval 0.048-0.926, P = 0.039).
Conclusions: Compared to the first two doses of the BNT162b2 vaccine given in pregnancy, the booster vaccination is safe and not associated with an increased rate of adverse obstetric and early neonatal outcomes.